I am just cross-posting what I read on Yahoo and helping the free flow of information. Jason Napodano, the Zacks analyst who is following and rating this stock, got basically the same information when he talked with them about 3 weeks ago.
In the scheme of things, NVIV has achieved what they set out to achieve for several really key milestones -- HUD approval and IDE approval way back in April, and calling in warrants successfully which set them up for the proper capital structure to uplist.
I am personally not trading this stock just on the exact date of either the uplist or the start of clinical implants of the biopolymer scaffold. Since they have a first rate team on board including spinal surgeons and other top doctors in the field, I have no doubts in my mind that the hospitals they are working with will allow trials to proceed.
Lastly, missing an uplist projection date is almost the rule rather than the exception with most stocks. You can read on NASDAQ and NYSE that the timeframe to uplist can occur within 6 to 8 weeks, but in the real world things don't happen that fast, you can cite dozens of stocks where 3 to 6 months was the norm from when they first announced their intentions. Furthermore, it is a very common scenario that minor changes to a BOD or other corporate modifications are stipulated by the Exchange as corrective action before a company is approved to uplist.
In conclusion, there is no reason to be distrustful that these things won't happen, nor is there a reason to doubt whether the company is making progress and anticipating they will happen at the dates indicated. As always, you can never time the events in virtually ANY biotech, and with NVIV at least we are not looking at predicting a binary outcome of an FDA approval or disapproval in the next 6 months, since the scaffold is regulated as a device and not a drug.
AI
Market Data 
Markets 
